{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T14:58:25Z","timestamp":1777820305521,"version":"3.51.4"},"reference-count":47,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:00:00Z","timestamp":1722038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Endovasc Ther"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Micronized purified flavonoid fraction (MPFF) is a widely prescribed and extensively investigated venoactive drug (VAD). The standard dosage for MPFF is 500 mg administered twice daily. However, a new daily dose of 1000 mg has just been introduced.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study investigated whether a daily dose of 1000 mg MPFF could be implemented and embraced by the public and still has the same therapeutic effects as conventional pharmaceuticals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>For this meta-analysis, we searched MEDLINE, Embase, Science of Web, Cochrane, and PubMed databases and forward and backward citations for studies published between database inception and March 2023. Three randomized controlled trials (RCTs) of comparison of different dosages of MPFF to evaluate whether there is a significant difference between them were included, without language or date restrictions. Due to the small sample size of the study included, we conducted a simple sensitivity test using a one-by-one exclusion method, and the results showed that the study did not affect the final consolidation conclusion. The quality of the evidence was assessed using the Cochrane risk-of-bias tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Out of 232 studies, 99 were eligible and 39 RCTs had data, all with low to moderate bias. Overall, 1924 patients (experimental group: 967, control group: 957) in 3 RCTs met the criteria. There is no significant difference in patient compliance, efficacy, clinical adverse events, and quality of life scores between MPFF 1000 mg once daily and MPFF 500 mg twice daily (standardized mean difference [SMD]: 0.049 [0.048, 0.145], p=0.321, risk ratio [RR]: 0.981 [0.855, 1.125], p=0.904, and SMD: 0.063 [0.034, 0.160], p=0.203).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation:<\/jats:title>\n                    <jats:p>In symptomatic chronic venous disease patients, MPFF 1000 mg once daily and MPFF 500 mg twice daily improve patient compliance, lower limb discomfort, clinical adverse events, and quality of life scores similarly. Regular medical care should recommend MPFF 1000 mg daily more often.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Impact<\/jats:title>\n                    <jats:list list-type=\"simple\">\n                      <jats:list-item>\n                        <jats:p>Micronized purified flavonoid fraction (MPFF) is a popular venoactive medication (VAD) in modern medicine.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>MPFF is effective in treating lower extremity venous problems.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Currently, besides conventional 500 mg tablets, there exist alternative dosage forms such as solutions, chewable tablets, and other novel formulations for MPFF.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>The excessive frequency and amount of medication may have a negative impact on patient adherence.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:sec>","DOI":"10.1177\/15266028241262700","type":"journal-article","created":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T03:02:36Z","timestamp":1722049356000},"page":"64-77","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["The Effects of Different Dosages on Micronized Purified Flavonoid Fraction\u2019s Treatment of Lower Limb Chronic Venous Disease: A Meta-Analysis"],"prefix":"10.1177","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5110-2301","authenticated-orcid":false,"given":"Hong-Jie","family":"Cui","sequence":"first","affiliation":[{"name":"Department of Vascular Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Feng","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Luhe Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,7,27]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab495"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/0003319718759834"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2004.05.015"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2020.07.006"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.2174\/1570161052773870"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19061669"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2021-0038"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0794-x"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01218-8"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-9590.18.03975-5"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2021.12.024"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-9590.21.04579-X"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1552043"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1302414"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116207"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl528"},{"issue":"10","key":"e_1_3_3_18_2","first-page":"914","article-title":"Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring","volume":"13","author":"Leenen FH","year":"1997","unstructured":"Leenen FH, Wilson TW, Bolli P, et al Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring. Can J Cardiol. 1997;13(10):914\u2013920.","journal-title":"Can J Cardiol"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-9590.22.04987-2"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/0268355518804455"},{"issue":"4","key":"e_1_3_3_23_2","first-page":"399","article-title":"Clinical acceptability study of once-daily versus twice-daily micronized purified flavonoid fraction in patients with symptomatic chronic venous disease: a randomized controlled trial","volume":"35","author":"Kirienko A","year":"2016","unstructured":"Kirienko A, Radak D. Clinical acceptability study of once-daily versus twice-daily micronized purified flavonoid fraction in patients with symptomatic chronic venous disease: a randomized controlled trial. Int Angiol. 2016;35(4):399\u2013405.","journal-title":"Int Angiol"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2014.09.003"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2019.12.075"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363010-00005"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-9590.19.04237-8"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1771041"},{"issue":"2","key":"e_1_3_3_29_2","first-page":"96","article-title":"Effects of micronized purified flavonoid fraction (Daflon) on pelvic pain in women with laparoscopically diagnosed pelvic congestion syndrome: a randomized crossover trial","volume":"34","author":"Simsek M","year":"2007","unstructured":"Simsek M, Burak F, Taskin O. Effects of micronized purified flavonoid fraction (Daflon) on pelvic pain in women with laparoscopically diagnosed pelvic congestion syndrome: a randomized crossover trial. Clin Exp Obstet Gynecol. 2007;34(2):96\u201398.","journal-title":"Clin Exp Obstet Gynecol"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-021-00312-6"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-021-00731-y"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/000331979404500602"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1039\/d0fo01598a"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24183316"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/350829"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-011-0038-3"},{"issue":"5","key":"e_1_3_3_37_2","first-page":"428","article-title":"Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial","volume":"34","author":"Rabe E","year":"2015","unstructured":"Rabe E, Agus GB, Roztocil K. Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. Int Angiol. 2015;34(5):428\u2013436.","journal-title":"Int Angiol"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-9590.18.04054-3"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-9590.18.03999-8"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003230.pub4"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-0884-4"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01217-9"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0149-2918(01)80109-0"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2009.15.9.728"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-013-0020-5"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-046860"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00670-0"},{"issue":"4","key":"e_1_3_3_48_2","first-page":"393","article-title":"Compliance in pharmacotherapy in patients with chronic venous disorders","volume":"31","author":"Chudek J","year":"2012","unstructured":"Chudek J, Koce\u0142ak P, Ziaja D, et al Compliance in pharmacotherapy in patients with chronic venous disorders. Int Angiol. 2012;31(4):393\u2013401.","journal-title":"Int Angiol"}],"container-title":["Journal of Endovascular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15266028241262700","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15266028241262700","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15266028241262700","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:30:48Z","timestamp":1777498248000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15266028241262700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,27]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1177\/15266028241262700"],"URL":"https:\/\/doi.org\/10.1177\/15266028241262700","relation":{},"ISSN":["1526-6028","1545-1550"],"issn-type":[{"value":"1526-6028","type":"print"},{"value":"1545-1550","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,27]]}}}